Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant albumin-bound paclitaxel plus cisplatin chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2100044536Phase 4Not yet recruiting
- Sponsor
- The Ninth Hospital of the Joint Logistic Support Force of the People's Liberation Army
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Ninth Hospital of the Joint Logistic Support Force of the People's Liberation Army. Primary endpoints: One-year local progression-free rate and Pathologic complete response rate. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100044536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044536.